Spectris plc (‘Spectris’) (LSE: SXS), the productivity-enhancing instrumentation and controls company, today announces that Karim Bitar has been appointed to the Board as a Non-executive Director with effect from 1 July 2017.
Karim is currently Chief Executive of Genus plc, an agricultural biotechnology pioneer. Prior to joining Genus, Karim worked for more than 15 years with Eli Lilly and Company in the biopharmaceutical sector, where he was president of Lilly Europe, Canada and Australia. An ex-McKinsey and Company consultant, he also held management roles at Johnson and Johnson and the Dow Chemical Company.
Announcing the appointment, John Hughes, Chairman of Spectris said: “I am pleased that Karim has agreed to join the Board. His considerable international leadership experience combined with his notable background in life sciences technology driven companies will further strengthen the Spectris Board.”
There are no further details to be disclosed in respect of Listing Rule 9.6.13.
– ENDS –
Contacts:
Spectris plc
Siobhán Andrews, Head of Corporate Affairs
+44 1784 470470
FTI Consulting
Richard Mountain / Susanne Yule
+44 203 727 1340
ABOUT SPECTRIS
Spectris plc is a leading supplier of productivity-enhancing instrumentation and controls. The Company’s products and technologies help customers to improve product quality and performance, improve core manufacturing processes, reduce downtime and wastage and reduce time to market. Its global customer base spans a diverse range of end user markets. Spectris operates across four business segments which reflect the applications and industries it serves: Materials Analysis, Test and Measurement, In-line Instrumentation and Industrial Controls. Headquartered in Egham, Surrey, United Kingdom, the Company employs around 8,900 people with offices in more than 30 countries. For more information, visit www.spectris.com (http://www.spectris.com).